Bicara Therapeutics (BCAX)

Healthcare · Biotechnology
$17.50 +1.39% on the day Market cap $1.1B 52-week range $13.70 to $30.99 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Bicara Therapeutics's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

D

Five factors scored 1 to 9 from BCAX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation5
Profitability0
Financial health9

Results from SEC filings

Fiscal years, from Bicara Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year202320242025
Revenue———
Net income-$52M-$68M-$138M
Free cash flow-$46M-$75M-$107M
EPS (diluted)-$89.61-$4.05-$2.52
Operating margin———

Superinvestors who own BCAX

From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Hersh Cohen
ClearBridge Investments
Added $9M0.01%Q2 2026
Cliff Asness
AQR Capital Management
Added $888,2360.0%Q2 2026

Insider buying

Open-market purchases by Bicara Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of BCAX in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when BCAX trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Bicara Therapeutics insiders buying the stock?

No open-market insider purchases of BCAX in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Bicara Therapeutics?

2 of the superinvestors Investingly tracks hold BCAX in their latest 13F, including Hersh Cohen, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.